These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 22266127)

  • 21. Nanotechnology controlled drug delivery for treating bone diseases.
    Yang L; Webster TJ
    Expert Opin Drug Deliv; 2009 Aug; 6(8):851-64. PubMed ID: 19637973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enzyme-responsive nanomaterials for controlled drug delivery.
    Hu Q; Katti PS; Gu Z
    Nanoscale; 2014 Nov; 6(21):12273-86. PubMed ID: 25251024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Developments in Nanomedicines for Management of Various Health Issues Via Metabolism and Physico-Chemical Properties.
    Rasool M; Naseer MI; Malik A; Manan A; Ullah I; Abid NB; Kim MO; Qazi MH; Kamal MA; Bibi F
    Curr Drug Metab; 2015; 16(5):389-96. PubMed ID: 25429671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanotechnology: emerging tool for diagnostics and therapeutics.
    Chakraborty M; Jain S; Rani V
    Appl Biochem Biotechnol; 2011 Nov; 165(5-6):1178-87. PubMed ID: 21847590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanoparticle formulations in pulmonary drug delivery.
    Bailey MM; Berkland CJ
    Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The performance of nanocarriers for transmucosal drug delivery.
    Csaba N; Garcia-Fuentes M; Alonso MJ
    Expert Opin Drug Deliv; 2006 Jul; 3(4):463-78. PubMed ID: 16822222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protease-triggered bioresponsive drug delivery for the targeted theranostics of malignancy.
    Li Y; Zhang C; Li G; Deng G; Zhang H; Sun Y; An F
    Acta Pharm Sin B; 2021 Aug; 11(8):2220-2242. PubMed ID: 34522585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzyme responsive drug delivery systems in cancer treatment.
    Shahriari M; Zahiri M; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    J Control Release; 2019 Aug; 308():172-189. PubMed ID: 31295542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug delivery systems: entering the mainstream.
    Allen TM; Cullis PR
    Science; 2004 Mar; 303(5665):1818-22. PubMed ID: 15031496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanoparticles and DNA - a powerful and growing functional combination in bionanotechnology.
    Samanta A; Medintz IL
    Nanoscale; 2016 Apr; 8(17):9037-95. PubMed ID: 27080924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biodegradable polymeric nanoparticles based drug delivery systems.
    Kumari A; Yadav SK; Yadav SC
    Colloids Surf B Biointerfaces; 2010 Jan; 75(1):1-18. PubMed ID: 19782542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-time electrochemical monitoring of drug release from therapeutic nanoparticles.
    Mora L; Chumbimuni-Torres KY; Clawson C; Hernandez L; Zhang L; Wang J
    J Control Release; 2009 Nov; 140(1):69-73. PubMed ID: 19679152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances and challenges of nanotechnology-based drug delivery systems.
    Jiang W; Kim BY; Rutka JT; Chan WC
    Expert Opin Drug Deliv; 2007 Nov; 4(6):621-33. PubMed ID: 17970665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes.
    Souto EB; Müller RH
    Handb Exp Pharmacol; 2010; (197):115-41. PubMed ID: 20217528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted drug delivery using immunoconjugates: principles and applications.
    Pasquetto MV; Vecchia L; Covini D; Digilio R; Scotti C
    J Immunother; 2011; 34(9):611-28. PubMed ID: 21989410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inorganic nanomedicine--part 1.
    Sekhon BS; Kamboj SR
    Nanomedicine; 2010 Aug; 6(4):516-22. PubMed ID: 20417313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mesoporous silica nanoparticles for bioadsorption, enzyme immobilisation, and delivery carriers.
    Popat A; Hartono SB; Stahr F; Liu J; Qiao SZ; Qing Max Lu G
    Nanoscale; 2011 Jul; 3(7):2801-18. PubMed ID: 21547299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug delivery from ordered mesoporous matrices.
    Manzano M; Colilla M; Vallet-Regí M
    Expert Opin Drug Deliv; 2009 Dec; 6(12):1383-400. PubMed ID: 19941412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanoparticle-enzyme hybrid systems for nanobiotechnology.
    Willner I; Basnar B; Willner B
    FEBS J; 2007 Jan; 274(2):302-9. PubMed ID: 17181543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications.
    Fleige E; Quadir MA; Haag R
    Adv Drug Deliv Rev; 2012 Jun; 64(9):866-84. PubMed ID: 22349241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.